Skip to content

Current Projects


The Biomedical Prevention Implementation Collaborative is pioneering an innovative, integrated approach to product introduction, with a focus on injectable cabotegravir for PrEP (CAB for PrEP/injectable CAB). BioPIC has developed a product introduction strategy that identifies priorities for rapid and successful scale-up. This shared strategy can forge a new path for HIV prevention and catalyze accelerated access to a growing portfolio of products in countries burdened by HIV. Learn more and find resources here. BioPIC is funded by the Bill & Melinda Gates Foundation and established in partnership with AVAC, CHAI and Viiv Healthcare. More on BioPIC here.

DREAMS Programs

Launched in 2014, the DREAMS Initiative aims to reduce the incidence of HIV by 40 percent among adolescent girls and young women by 2020. It is a collaboration between the US President’s Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences and ViiV Healthcare.

The PEPFAR Scientific Advisory Board has endorsed PrEP and launched a DREAMS Innovation Challenge, to make more resources available for PrEP.

DREAMS is operating in ten countries, five of which have included PrEP for adolescent girls and young women in their country plans to address HIV.


Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a five-year (2021-2026) global project funded by PEPFAR through USAID to help adolescent girls and young women, and other women, prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products. MOSAIC works across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide range of local partners to perform essential functions that support the introduction of HIV prevention products.

For a two-page overview of the project, click here. To learn more and find related resources, click here. And for the MOSAIC Global PrEP Learning Network, click here.

Former Projects

Bridge to Scale (Jilinde)

The Bridge to Scale, or Jilinde, project was an implementation science initiative that sought to move oral pre-exposure prophylaxis (PrEP) from research and demonstration settings into a large-scale public health response in Kenya. Over 20,000 people at highest risk of HIV infection received oral PrEP, which was integrated within existing HIV combination prevention services. This project demonstrated the incredible potential of PrEP and generated evidence that population-level PrEP interventions are feasible and effective in low-and middle-income countries, which bear the brunt of the world’s HIV burden. Bridge to Scale began delivering PrEP in early 2017 and ran until June 2021.

The project functioned as a learning laboratory to identify and document the barriers and enablers to PrEP uptake. Ultimately, the project developed an affordable, effective, sustainable and replicable model for oral PrEP scale-up. For an overview of the project, click here.

OPTIONS and Other USAID Microbicide Product Introduction Initiative (MPii) Projects

The US Agency for International Development (USAID) supported five connected projects focused on introducing and providing access to ARV-based HIV prevention. These projects, which ran from 2015-2020, focused on gender-based violence, drug resistance, creating demand, introducing new products, and models for delivering services. For a more detailed look at each of the five MPii projects, click here. And to see Tools & Resources from these projects, click here.

Prevention Market Manager Project

Established in 2016, The Prevention Market Manager (PMM) was a comprehensive, collaborative project to accelerate the introduction of HIV prevention products to effectively reach those who need prevention most. It was funded by the Bill & Melinda Gates Foundation (BMGF) and was a six year effort in partnership with The Clinton Health Access Initiative (CHAI). For more about the project, and for several resources, click here.


CHOICE (Collaboration for HIV Prevention Options to Control the Epidemic) and PROMISE (Preparing for Ring Opportunities through Market Introduction Support and Knowledge Exchange) were USAID-funded activities harnessing research utilization expertise to address technical gaps and scale up the use of PrEP (both oral PrEP and the monthly PrEP ring) in sub-Saharan Africa. To read more about CHOICE’s work, download this overview. To read more about PROMISE and CHOICE work on the ring, download this overview. To see tools & resources related to these projects, click here.


PEPFAR (US President’s Emergency Plan for AIDS Relief)

Working in over 50 countries, PEPFAR has transformed the global HIV/AIDS response by supporting nearly 19 million people with antiretroviral treatment, a 171 percent increase since 2014. This is compared with the only 50,000 people who were on treatment in sub-Saharan Africa when PEPFAR began in 2003.

PEPFAR is now supporting rollout of PrEP. Click here to explore quarterly PEPFAR data, including the “number of adults and adolescents who received PrEP”. Click here to view PEPFAR “Country Operational Plans (COPs)” which outline PEPFAR yearly plans, country-by-country. Many COPs include provisions for PrEP.

The Global Fund

The Global Fund to Fight AIDS, Tuberculosis and Malaria invests over US$1 billion per year to build resilient and sustainable systems for health, making it one of the largest funders in the world for global health. Its investments sustain and strengthen access to lifesaving services, including direct support to community-led responses.

The Global Fund is investing in data systems and delivery platforms so that community-based service providers can make informed decisions about what to prioritize in HIV prevention. The Global Fund is investing in enhanced condom programs, expanding PrEP access, voluntary medical male circumcision, and harm reduction services for people who use drugs, and accelerating adoption and use of proven new HIV prevention products such as the dapivrine vaingal ring (PrEP ring) and new formulations for PrEP, such as injectable cabotegravir.


Unitaid works with countries and healthcare partners to identify shortcomings in the way the global community is responding to HIV, tuberculosis and malaria. Unitaid prioritizes expanding the reach of the best health products for those who need them most. In the field of HIV prevention, Unitaid initiatives are expanding HIV self-testing in Africa, funding HIV programs to integrate injectable CAB into their services, and gathering data to generate crucial real-world evidence that will underpin efforts for rapid global scale-up.

Normative Agencies

World Health Organization

The World Health Organization’s Global Health Sector Strategies for HIV, 2022-2030 includes a renewed focus on primary prevention and leveraging innovation in new prevention approaches. This plan calls for an optimal mix of HIV prevention interventions that is grounded in data and addresses individual needs and preferences. The strategic combination of pre-exposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) with other prevention interventions, or the use of antiretroviral drugs by people who are not infected with HIV, should be offered as an additional prevention choice. The WHO also supports the PrEP ring as an additional prevention choice for women, noting that only one vaginal ring product was available in 2022, but other injectable and implantable PrEP formulations are expected to become available during the 2022-2030 strategy implementation period.